Long COVIDLongCovidRehabNCT07046208
Effects os Physiotherapeutic Rehabilitation on Function Autonomic and Inflammatory in Patients With Long Covid
A study testing physiothreapy protocol in people with Long COVID and Heart Rate Variability (HRV), run by Universidade do Estado do Pará.
Trial summary
Introduction: Long COVID is characterized by persistent symptoms that persist for weeks or months after the acute phase of infection, with a significant impact on the cardiovascular and autonomic systems. Read more about this study
- Who is it for?
- Ages 20 to 59 years
- Conditions the study is for
- Long COVID, Heart Rate Variability (HRV), Cardiac Biomarkers
- What is being tested?
- physiothreapy protocol
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 58 participants
- Where
- No sites listed yet
- Study dates
- 11 Aug 2025to 30 Sep 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 to 59 years
- All sexes
- No healthy volunteers
- Adult
Who may be able to join
- both sexes
- aged 20 and 59 years
- clinical evaluation and undergoing clinical follow-up of Post COVID-19.
- least one persistent COVID-19-related symptom.
Who cannot join
- incomplete data.
- presence of a pacemaker
- use of antihypertensive drugs that alter HRV
- persistent pulmonary alterations
- persistent desaturation
- anaemia or presence of reinfection.
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
Official title: Effects os Physiotherapeutic Rehabilitation on Cardiovascular Autonomic Modulation and Biomarkers Inflammatory and Cardiac Conditions in Patients With Long Covid
Introduction: Long COVID is characterized by persistent symptoms that persist for weeks or months after the acute phase of infection, with a significant impact on the cardiovascular and autonomic systems. Objectives: This study aims to evaluate the effects of a physiotherapeutic rehabilitation protocol on cardiovascular autonomic modulation and on inflammatory and cardiac biomarkers in patients with Long COVID. Methodology: This is a controlled clinical trial, carried out in a cardiorespiratory rehabilitation outpatient clinic, involving individuals with a clinical diagnosis of Long COVID undergoing a protocol of 20 aerobic, anaerobic and respiratory rehabilitation sessions. Heart rate variability (HRV) variables will be analyzed using linear and non-linear methods, in addition to serum levels of CKMB, LDH, ferritin and C-reactive protein. Expected results: Rehabilitation is expected to provide an improvement in autonomic function and a reduction in inflammatory and cardiac markers, contributing to the understanding of the pathophysiological mechanisms of Long COVID and helping to propose evidence-based therapeutic strategies.
- Being tested
- physiothreapy protocol
- Medical subject headings
- Post-Acute COVID-19 Syndrome
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
physiothreapy protocolOther
Aerobic training (treadmill or exercise bike) for 15 minutes, anaerobic training at the weight training station, performing exercises for the upper limbs (bench press and front pull) and lower limbs (180º leg press and extension chair) with weight determined by the 1 Repetition Maximum (1RM) test, performing 3 sets of 12-15 repetitions (depending on the session) and respiratory muscle training using POWERbreathe (30-40% of the MIP performed in the manovacuometry test).
| Study group | Role | What they receive |
|---|---|---|
| Rehabilitation for long covid | Experimental | Physioterapy protocol Receives: Other: physiothreapy protocol |
What is being measured
The primary outcome is the main question the study is designed to answer.
Autonomic Modulation
cardiofrequency meter
Measured: Before and afther the intervention 3 months.
Secondary outcomes (1)
Inflammation
the cardiac and inflammatory biomarkers, creatine phosphokinase isoenzyme MB (CKMB) associated with lactate dehydrogenase (LDH) and ferritin can be analysed.
Measured: Before and the afther 3 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 Jul 2025
- Study start11 Aug 2025 (estimated)
- Primary completion10 Aug 2026 (estimated)
- Study completion30 Sep 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Long COVIDStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 58 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Universidade do Estado do Pará
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Luiz Fábio Magno Falcão, PhD, Universidade do Estado do Pará
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07046208
- Sponsor's protocol ID
- 36459920400005174
- Other IDs
- 4252664
- Acronym
- LongCovidRehab
- Status last verified
- Jun 2025
- First submitted
- 29 Jun 2025
- Last updated
- 1 Jul 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Marques KC, Silva CC, Trindade SDS, Santos MCS, Rocha RSB, Vasconcelos PFDC, Quaresma JAS, Falcao LFM. Reduction of Cardiac Autonomic Modulation and Increased Sympathetic Activity by Heart Rate Variability in Patients With Long COVID. Front Cardiovasc Med. 2022 Apr 29;9:862001. doi: 10.3389/fcvm.2022.862001. eCollection 2022.
PubMed 35571200
Study at a glance
From the registry record, last updated by the sponsor on 1 Jul 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effects os Physiotherapeutic Rehabilitation on Cardiovascular Autonomic Modulation and Biomarkers Inflammatory and Cardiac Conditions in Patients With Long Covid
- ClinicalTrials.gov ID
- NCT07046208
- Acronym / sponsor ID
- LongCovidRehab / 36459920400005174
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 58 participants (estimated)
- Lead sponsor
- Universidade do Estado do ParáUniversity, hospital or other
- Study start
- 11 Aug 2025 (estimated)
- Primary completion
- 10 Aug 2026 (estimated)
- Study completion
- 30 Sep 2026 (estimated)
- First posted
- 1 Jul 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Introduction: Long COVID is characterized by persistent symptoms that persist for weeks or months after the acute phase of infection, with a significant impact on the cardiovascular and autonomic systems. Objectives: This study aims to evaluate the effects of a physiotherapeutic rehabilitation protocol on cardiovascular autonomic modulation and on inflammatory and cardiac biomarkers in patients with Long COVID. Methodology: This is a controlled clinical trial, carried out in a cardiorespiratory rehabilitation outpatient clinic, involving individuals with a clinical diagnosis of Long COVID undergoing a protocol of 20 aerobic, anaerobic and respiratory rehabilitation sessions. Heart rate variability (HRV) variables will be analyzed using linear and non-linear methods, in addition to serum levels of CKMB, LDH, ferritin and C-reactive protein. Expected results: Rehabilitation is expected to provide an improvement in autonomic function and a reduction in inflammatory and cardiac markers, contributing to the understanding of the pathophysiological mechanisms of Long COVID and helping to propose evidence-based therapeutic strategies.
Study design
- Primary purpose
- Supportive care
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Rehabilitation for long covid | Experimental | Other: physiothreapy protocolPhysioterapy protocol |
Who may qualify
- Ages
- 20 to 59 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (4 listed)
- both sexes
- aged 20 and 59 years
- clinical evaluation and undergoing clinical follow-up of Post COVID-19.
- least one persistent COVID-19-related symptom.
Key exclusion criteria (6 listed)
- incomplete data.
- presence of a pacemaker
- use of antihypertensive drugs that alter HRV
- persistent pulmonary alterations
- persistent desaturation
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| physiothreapy protocolAerobic training (treadmill or exercise bike) for 15 minutes, anaerobic training at the weight training station, performing exercises for the upper limbs (bench press and front pull) and lower limbs (180º leg press and extension chair) with weight determined by the 1 Repetition Maximum (1RM) test, performing 3 sets of 12-15 repetitions (depending on the session) and respiratory muscle training using POWERbreathe (30-40% of the MIP performed in the manovacuometry test). | Other | Rehabilitation for long covid |
Primary outcome
Autonomic Modulation
Time frame: Before and afther the intervention 3 months.
cardiofrequency meter
1 secondary outcome
Inflammation
Time frame: Before and the afther 3 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 1 Jul 2025.
- Results publication: PubMed 35571200Marques KC, Silva CC, Trindade SDS, Santos MCS, Rocha RSB, Vasconcelos PFDC, Quaresma JAS, Falcao LFM. Reduction of Cardiac Autonomic Modulation and Increased Sympathetic Activity by Heart Rate Variability in Patients With Long COVID. Front Cardiovasc Med. 2022 Apr 29;9:862001. doi: 10.3389/fcvm.2022.862001. eCollection 2022.
- Individual participant dataSharing planned: No
Related trials for Long COVID
Recruiting
Whole-body Cryotherapy in Those With Chronic Fatigue: A Feasibility Study
ME/CFS, Fibromyalgia (FM)
Active, not recruitingObservational study
Epigenetic Changes in Long COVID Patients
Long COVID-19 Syndrome, Long COVID Symptoms
Not yet recruitingPhase 3
Dapagliflozin for Long COVID Syndrome
COVID - 19, Long COVID Syndrome
Active, not recruiting
Long COVID Brain Fog: Cognitive Rehabilitation Trial
Long COVID, Brain Fog
RecruitingPhase 2
SARS-CoV-2 and Herpesvirus Inhibition for Ending Long COVID Dysfunction
Post-acute Sequelae of COVID-19, Long COVID
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Questions about this trial
What is this clinical trial studying?
A study testing physiothreapy protocol in people with Long COVID and Heart Rate Variability (HRV), run by Universidade do Estado do Pará.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 1 Jul 2025. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Luiz Magno Falcão, Research and coordinator (+5591982379488, fabiofalcao@uepa.br), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Autonomic Modulation (time frame: Before and afther the intervention 3 months.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07046208, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Jul 2025; AzTrials last refreshed its copy on 6 Nov 2026.